Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Pediatr Transplant ; 17(1): 65-72, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22882667

RESUMEN

CKD is a frequent long-term complication after SBTx. CNIs are a well-known factor, but probably not the only cause. We assessed the incidence, risk factors, and severity of CKD in 27 children with SBTx (15 combined liver/SBTx) and prednisone/TAC-based maintenance immunosuppression. Median follow-up was seven yr (3-21). A renal biopsy was performed in 14 patients, 1-18 yr post-SBTx. A reduced GFR was observed in 17 children (63%) during the follow-up with none requiring dialysis. CNI toxicity was observed in 11/14 biopsies, as early as two yr post-transplant, and could occur with a normal mGFR. The dose of TAC was reduced by 50% in 13 patients with CKD and/or significant kidney histological lesions, and six were also given MMF. This led to a significant improvement in renal function: mGFR normalized in eight patients and improved or stabilized in five. No rejection occurred. At last follow-up, 37% had CKD stage 2 and 15% had CKD stage 3. In conclusion, CKD is frequent in children after SBTx and probably multifactorial. Less nephrotoxic immunosuppressive protocols may improve mGFR and should be further considered. The kidney histology helps in designing personalized immunosuppression strategies for patients.


Asunto(s)
Intestino Delgado/trasplante , Insuficiencia Renal/etiología , Trasplante/efectos adversos , Adolescente , Niño , Preescolar , Femenino , Estudios de Seguimiento , Tasa de Filtración Glomerular , Rechazo de Injerto , Supervivencia de Injerto , Humanos , Inmunosupresores/uso terapéutico , Incidencia , Lactante , Enfermedades Intestinales/cirugía , Masculino , Insuficiencia Renal/epidemiología , Factores de Riesgo , Tacrolimus/uso terapéutico , Resultado del Tratamiento
2.
Am J Kidney Dis ; 53(6): 1063-7, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19084310

RESUMEN

Pauci-immune renal vasculitis is associated strongly with antineutrophil cytoplasmic antibodies (ANCAs) of the immunoglobulin G (IgG) class, which are detected in 80% to 90% of affected patients. IgA ANCAs have been reported in association with various conditions, but never in the setting of pauci-immune vasculitis. A 28-year-old man with unexplained polyclonal hyper-IgA1 diagnosed in childhood presented with decreased kidney function, nephrotic syndrome, and microscopic hematuria. Kidney biopsy showed pauci-immune crescentic glomerulonephritis. Serum test results were negative for IgG ANCA by means of both indirect immunofluorescence and enzyme-linked immunosorbent assay techniques. Conversely, indirect immunofluorescence performed using anti-IgA antibody was strongly positive with a cytoplasmic ANCA pattern, and an enzyme-linked immunosorbent assay test had positive results for both antimyeloperoxidase and anti-proteinase 3 IgA. IgA ANCAs were not detected in 2 control serum samples from 1 patient with polyclonal hyper-IgA and 1 patient with monoclonal hyper-IgA. The patient received corticosteroids and 4 weekly perfusions of rituximab (375 mg/m2). After a 6-month follow-up, decreased kidney function and nephrotic syndrome persisted and IgA ANCA titers were unchanged. However, a control kidney biopsy showed a decrease in vasculitis activity. This first case of pauci-immune vasculitis associated with ANCA of the IgA class suggests the potential pathogenetic role of these peculiar antibodies. Additional studies are needed to determine whether IgA ANCAs, which are not routinely screened for, can be detected in patients with pauci-immune vasculitis either alone or in association with IgG ANCA.


Asunto(s)
Anticuerpos Anticitoplasma de Neutrófilos/sangre , Glomerulonefritis por IGA/inmunología , Inmunoglobulina A/sangre , Adulto , Anticuerpos Anticitoplasma de Neutrófilos/biosíntesis , Glomerulonefritis por IGA/diagnóstico , Glomerulonefritis por IGA/patología , Humanos , Inmunoglobulina A/biosíntesis , Masculino , Vasculitis/diagnóstico , Vasculitis/inmunología , Vasculitis/patología
3.
Curr Opin Gastroenterol ; 24(6): 742-8, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19122524

RESUMEN

PURPOSE OF REVIEW: Autoimmune enteropathy (AIE) is a distinct cause of severe and persistent inflammatory diarrhea in children. Recent research data allowed us to gain a first insight in the pathogenesis of AIE. On the basis of this data, we will discuss new aspects of AIE emphasizing new diagnostic and therapeutic possibilities. RECENT FINDINGS: With the discovery of disease-causing mutations in the FOXP3 gene in patients with AIE, a dramatic advance in the understanding of AIE was made. Subsequent studies indicated that FOXP3 is a key transcription factor indispensable for regulatory functions of T cells pointing to a critical role of regulatory T-cell homeostasis in the development of AIE. Abnormal FOXP3 expression results in defective regulatory functions of T cells, which in turn cause a systemic T-cell-mediated autoaggressive disorder, now called immune dysregulation, polyendocrinopathy autoimmune enteropathy X-linked syndrome. Upon systematic review, we describe different phenotypes of immune dysregulation polyendocrinopathy autoimmune enteropathy X-linked syndrome, as well as immune dysregulation polyendocrinopathy autoimmune enteropathy X-linked-like forms of AIE, which are FOXP3 independent. No genotype-phenotype correlation could be established so far. SUMMARY: On the basis of the profound immune dysregulation in AIE, new, most often T-cell-oriented treatment strategies were developed. The recent molecular advances in the understanding of AIE give a clear rational for the use of immunosuppression (combining steroids and tacrolimus or rapamycine) to stabilize AIE patients or to perform bone marrow transplantation in those who do not respond to immunomodulation.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Enfermedades Genéticas Ligadas al Cromosoma X/inmunología , Terapia de Inmunosupresión/métodos , Enfermedades Intestinales/inmunología , Poliendocrinopatías Autoinmunes/inmunología , Animales , Enfermedades Autoinmunes/genética , Enfermedades Autoinmunes/terapia , Autoinmunidad , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Enfermedades Genéticas Ligadas al Cromosoma X/terapia , Predisposición Genética a la Enfermedad , Humanos , Enfermedades Intestinales/genética , Enfermedades Intestinales/terapia , Poliendocrinopatías Autoinmunes/genética , Poliendocrinopatías Autoinmunes/terapia
4.
Gut ; 56(10): 1379-86, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17303598

RESUMEN

BACKGROUND/AIMS: Whether a life-long gluten-free diet (GFD) is necessary in all children with diagnosed coeliac disease (CD) remains debated. To address this question, a retrospective analysis of the clinical and biological status of adult coeliac patients diagnosed in childhood, who remained on a normal diet after gluten challenge and were clinically silent, was carried out. METHODS: Patients aged 18-65 years with CD diagnosed in childhood were included. Clinical status, gluten intake, biological parameters of malabsorption, bone mineral density, human leucocyte antigen (HLA) genotype, serological markers of CD, and histological and immunohistochemical parameters in duodenal biopsies were recorded. RESULTS: Sixty-one patients had resumed a normal diet and were asymptomatic. Forty-eight showed different degrees of villous atrophy (silent CD), while 13 had no detectable atrophy (latent CD) on duodenal biopsies. Latent CD patients had significantly less osteopenia/osteoporosis (1/9 (11%) vs 23/33 (70%), p<0.001)), and lower T cell receptor (TCR) alphabeta+ intraepithelial T cell counts (38+/-20 vs 55+/-15, p<0.01) than silent CD patients. The mean age at diagnosis and first GFD was lower in latent than in silent patients (14.4+/-5 vs 40.1+/-47 months, p<0.05). Latent patients did not differ significantly from the seven control patients on a long-term GFD, except for a higher frequency of CD-specific serum antibodies. However, two latent patients relapsed clinically and histologically during subsequent follow-up. CONCLUSIONS: Long-term latency developed in about 20% of CD patients who remained symptom free after gluten reintroduction. This latency can be transient and thus a regular follow-up is mandatory. In silent patients, the increased risk of osteoporosis substantiates the need for a GFD.


Asunto(s)
Enfermedad Celíaca/dietoterapia , Glútenes/administración & dosificación , Adolescente , Adulto , Anciano , Atrofia , Autoanticuerpos/sangre , Densidad Ósea , Enfermedad Celíaca/inmunología , Enfermedad Celíaca/patología , Enfermedad Celíaca/fisiopatología , Duodeno/patología , Femenino , Estudios de Seguimiento , Prueba de Histocompatibilidad , Humanos , Mucosa Intestinal/patología , Masculino , Persona de Mediana Edad , Estado Nutricional , Pronóstico , Estudios Retrospectivos , Transaminasas/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA